Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Osteoporosis 1Neoplasms 1Musculoskeletal Diseases 1Hyperparathyroidism 1Humoral Hypercalcemia Of Malignancy 1Endocrine System Diseases 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × parathyroid hormone-related peptide (1-36) × Clear all
NCT00580788 2016-02-11

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

University of Pittsburgh

Phase EARLY_PHASE1 Completed
14 enrolled 16 charts
Head & Neck

Humoral Hypercalcemia Of Malignancy, Endocrine System Diseases, Hyperparathyroidism, Musculoskeletal Diseases, Neoplasms, Osteoporosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡